iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Lupin hits 52-week high on tentative USFDA approval for dapagliflozin and saxagliptin tablets

5 Jan 2024 , 11:32 AM

Lupin Limited’s shares hit a 52-week high of Rs 1,429.95 in early trade on January 5 after the company said that the US Food and medicine Administration (USFDA) had granted it preliminary permission to commercialize a generic diabetic medicine.

At around 11.03 AM, Lupin was trading 0.39% lower at Rs 1,393.55 per piece, against the previous close of Rs 1,399 on NSE.

The Mumbai-based company announced on January 4 that it has obtained approval from the American regulator for its abbreviated new drug application for dapagliflozin and saxagliptin tablets. The product serves as a generic counterpart to AstraZeneca AB’s Qtern tablets.

Lupin plans to manufacture the drug at its Pithampur Facility in Madhya Pradesh.

Dapagliflozin and saxagliptin tablets are used to enhance glycemic control in persons with type 2 diabetes in addition to diet and exercise.

The FDA approved the pharma company’s generic loteprednol etabonate ophthalmic fluid for seasonal allergic conjunctivitis in December.

Lupin Atlantis Holdings SA, Switzerland, a wholly-owned subsidiary of the firm, has agreed to purchase a portfolio of established pharmaceuticals in Europe and Canada from Sanofi, a French multinational pharmaceutical and healthcare company, for EUR 10 million (Rs 91 crore).

For feedback and suggestions, write to us at editorial@iifl.com

explored-media

Related Tags

  • Lupin
  • Lupin News
  • Lupin Updates
  • Lupin USFDA Approval
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.